This HTML5 document contains 81 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/AHFS/
n8http://linked.opendata.cz/resource/drugbank/drug/DB06782/identifier/wikipedia/
n10http://linked.opendata.cz/resource/mesh/concept/
n6http://linked.opendata.cz/resource/drugbank/drug/DB06782/identifier/pharmgkb/
n25http://linked.opendata.cz/resource/drugbank/dosage/
n13http://linked.opendata.cz/resource/drugbank/mixture/
n22http://linked.opendata.cz/resource/drugbank/drug/DB06782/identifier/kegg-compound/
n17http://linked.opendata.cz/resource/drugbank/drug/DB06782/identifier/pubchem-compound/
n26http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB06782/identifier/kegg-drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB06782/identifier/pubchem-substance/
n21http://linked.opendata.cz/resource/drugbank/drug/DB06782/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/drug/DB06782/identifier/national-drug-code-directory/
n9http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/drugbank/drug/DB06782/identifier/chemspider/
n23http://linked.opendata.cz/resource/drugbank/drug/DB06782/identifier/chebi/
n16http://linked.opendata.cz/resource/atc/
n14http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06782
rdf:type
n3:Drug
n3:description
Dimercaprol is a traditional chelating agent developed by British biochemists at Oxford University during World War II. It was developed as an experimental antidote against the arsenic-based poison gas Lewisite. It has been used clinically since 1949 in arsenic, cadmium and mercury poisoning. In addition, it has in the past been used for the treatment of Wilson's disease, a genetic disorder in which the body tends to retain copper. Dimercaprol is a potentially toxic drug, and its use may be accompanied by multiple side effects.
n3:dosage
n25:271B545D-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Walshe JM: The conquest of Wilson's disease. Brain. 2009 Aug;132(Pt 8):2289-95. Epub 2009 Jul 13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19596747 # Boscolo M, Antonucci S, Volpe AR, Carmignani M, Di Gioacchino M: Acute mercury intoxication and use of chelating agents. J Biol Regul Homeost Agents. 2009 Oct-Dec;23(4):217-23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20003760 # Flora SJ, Pachauri V: Chelation in metal intoxication. Int J Environ Res Public Health. 2010 Jul;7(7):2745-88. Epub 2010 Jun 28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20717537 # Andersen O: Chemical and biological considerations in the treatment of metal intoxications by chelating agents. Mini Rev Med Chem. 2004 Jan;4(1):11-21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14754439
n3:group
approved
n3:halfLife
The drug has a short half life.
n3:indication
For the treatment of arsenic, gold and mercury poisoning. Indicated in acute lead poisoning when used concomitantly with edetate calcium disodium (DB00974).
owl:sameAs
n12:DB06782 n26:DB06782
dcterms:title
Dimercaprol
adms:identifier
n6:PA165958406 n8:Dimercaprol n17:3080 n18:99443293 n19:D00167 n20:11098-526-03 n21:DB06782 n22:C02924 n23:554382 n24:2971
n3:mechanismOfAction
The sulfhydryl groups of dimercaprol form complexes with certain heavy metals thus preventing or reversing the metallic binding of sulfhydryl-containing enzymes. The complex is excreted in the urine.
n3:routeOfElimination
Urine.
n3:synonym
1,2-Dimercapto-3-propanol 2,3-Mercaptopropanol British antilewisite Dithioglycerine 1,2-Dithioglycerol Dithioglycerol 2,3-Dimercapto-1-propanol British Anti-Lewisite 2,3-Dimercaptol-1-propanol Sulfactin 2,3-Dithiopropanol Dimercaprolum 2,3-Dimercapro 3-Hydroxy-1,2-propanedithiol alpha,beta-Dithioglycerol 2,3-Mercaptopropan-1-ol Dimercaptopropanol 2,3-Dimercaptopropanol BAL
n3:toxicity
The intramuscular LD50 in rats is approximately 105 mg/kg; intraperitoneally 140 mg/kg. The intraperitoneal LD80 in mice is approximately 125 mg/kg. Dimercaprol has been shown in animal experiments to increase brain deposition of arsenite, organic mercury compounds and increase the toxicity of cadmium and lead. Dimercaprol has been shown to induce seizure in animal studies and also is nephrotoxic.
n14:hasAHFSCode
n15:64-00-00
n3:mixture
n13:271B545B-363D-11E5-9242-09173F13E4C5 n13:271B545C-363D-11E5-9242-09173F13E4C5
n3:synthesisReference
Peppel, W.J. and Signaigo, F.K.; U.S. Patent 2,402,665; June 25,1946; assigned to E.I. du Pont de Nemwrs & Company.
n9:hasConcept
n10:M0006441
n3:IUPAC-Name
n4:271B5462-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5468-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5467-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5464-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5465-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5466-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5460-363D-11E5-9242-09173F13E4C5 n4:271B5478-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B545E-363D-11E5-9242-09173F13E4C5 n4:271B5461-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B545F-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B547B-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n16:V03AB09
n3:H-Bond-Acceptor-Count
n4:271B546E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B546F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5469-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B546A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B546C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B546B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B546D-363D-11E5-9242-09173F13E4C5
n3:absorption
After intra-muscular injection.
n3:casRegistryNumber
59-52-9
n3:category
n3:Bioavailability
n4:271B5474-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B547A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5476-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5477-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5479-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5473-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5472-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5475-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5463-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5470-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5471-363D-11E5-9242-09173F13E4C5